Scientists Develop Universal Ebola Treatment Effective in Single Dose
There is a new medication that in one dose successfully protected nonhuman primates against a lethal infection of all strains of the deadly Ebola virus. The findings are now available in Cell Host & Microbe.
Dr. Thomas Geisbert, an Ebola researcher at the University of Texas Medical Branch, said that previous therapeutics typically were of the "one bug, one drug" variety. But because of the unpredictable nature and variety of the Ebola virus, scientists have been seeking a way to protect against different strains of the virus.
"Our experimental drug can protect against all forms of Ebola known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," said Geisbert, who is a professor of microbiology and immunology at UTMB.
The team of scientists demonstrated that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections of caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain that caused the 2013-16 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo.
"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, president of Mapp Biopharmaceutical Inc. "Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions. The ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on healthcare workers in the field during outbreaks, especially in regions that have a less-developed infrastructure."
Other authors of this paper include UTMB's Chad Mire, Robert Cross, Joan Geisbert, Viktoriya Borisevich and Krystle Agans; Zachary Bornholdt, Dafna Abelson, William Shestowsky, Ognian Bohorov, Natasha Bohorova, Jesus Velasco, Eric Ailor, Do Kim, Michael Pauly and Kevin Whaley from Mapp Biopharmaceutical Inc.; Andrew Herbert, Rebekah James and John Dye from the United States Army Medical Research Institute of Infectious Diseases; Shihua He, Md Niaz Rahim, Wenjun Zhu, Logan Banadyga, Kevin Tierney and Xiangguo Qiu from the Public Health Agency of Canada; Anna Wec, Ariel Wirchnianski and Kartik Chandran from Albert Einstein College of Medicine; Bronwyn Gunn and Galit Alter from The Ragon Institute; Eileen Goodwin and Laura Walker from Adimab LLC.
Source: University of Texas Medical Branch
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
